BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 11777957)

  • 1. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
    Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
    Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
    Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
    Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
    Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
    Jongen-Lavrencic M; Salesse S; Delwel R; Verfaillie CM
    Leukemia; 2005 Mar; 19(3):373-80. PubMed ID: 15674360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
    Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
    Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).
    Chiorean EG; Dylla SJ; Olsen K; Lenvik T; Soignier Y; Miller JS
    Blood; 2003 May; 101(9):3527-33. PubMed ID: 12511422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia.
    Cho EK; Heo DS; Seol JG; Seo EJ; Chi HS; Kim ES; Lee YY; Kim BK; Kim NK
    Br J Haematol; 2000 Oct; 111(1):216-22. PubMed ID: 11091204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
    Zhao RC; Jiang Y; Verfaillie CM
    Blood; 2001 Apr; 97(8):2406-12. PubMed ID: 11290604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia: mechanisms underlying disease progression.
    Shet AS; Jahagirdar BN; Verfaillie CM
    Leukemia; 2002 Aug; 16(8):1402-11. PubMed ID: 12145676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in laboratory medicine in chronic myeloid leukemia].
    Miura A
    Rinsho Byori; 1998 Dec; 46(12):1226-31. PubMed ID: 9916508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.